Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: Implications for tumor aggressiveness and patient survival

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 529-535

  Cardoso Filho, Cassio ^a   Sarian, Luis Otavio ^a   De Oliveira, Camila Borges Martins ^a   Da Silveira Bossi, Leonardo ^a   Lourenço, Gustavo Jacob ^a   Lima, Carmen Silvia Passos ^a   Gurgel, Maria Salete Costa ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Breast neoplasm; Cytochrome P 450 CYP1A1; Polymorphism; Survival; Tamoxifen

Indexed keywords

ALANINE; CYSTEINE; CYTOCHROME P450 1A1; GLYCINE; TAMOXIFEN; THREONINE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CYP1A1 GENE; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREMENOPAUSE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TUMOR GENE; TUMOR INVASION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84883490786     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2221-y     Document Type: Article

References (26)

1. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764
2. Johnson MD, Zuo H, Lee KH et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159
3. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478
4. MacCallum J, Cummings J, Dixon JM, Miller WR (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 82:1629-1635
5. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A et al (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336-2343
6. Sharma M, Shubert DE, Sharma M et al (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact 146:237-249
7. Parte P, Kupfer D (2005) Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 33:1446-1452
8. van Schaik RH (2008) CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11:77-98
9. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075
10. Sun D, Sharma AK, Dellinger RW et al (2007) Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35:2006-2014
11. Nishiyama T, Ogura K, Nakano H et al (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4- hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830
12. Nowell S, Falany CN (2006) Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 25:1673-1678
13. Seruga B, Amir E (2010) Cytochrome P450 2D6 and outcomes of adjuvante tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 122(3):609-617
14. Abrahan JE, Maranian MJ, Driver KE et al (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12(4):R64
15. Parl FF, Dawling S, Roodi N, Crooke PS (2009) Estrogen metabolism and breast cancer: a risk model. Ann NY Acad Sci 1155:68-75
16. Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115-124
17. Oliveira C, Lourenço GJ, Silva PM et al (2011) Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumour Biol 32:295-300
18. Cardoso-Filho C, Lourenço GJ, Shinzato JY, Zeferino LC, Costa FF (2008) Clinical and pathological implications of GSTM1 and GSTT1 gene deletions in sporadic breast cancer. Oncol Rev 2:36-43
19. Woodhead JL, Fallon R, Figuered H, Longdale J, Malcom AD (1986) Alternative methodology of gene diagnosis. In: Davies KE (ed) Human genetic diseases: a practical approach. IRL Press, Oxford, pp 51-64
20. Canalle R, Burim RV, Tone LG, Takahashi CS (2004) Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 43:100-109
21. Wang J, Deng Y, Li L et al (2003) Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci 94:448-452
22. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M (2004) Genetic polymorphisms of CYP1A1, CYP2D6, GSTM1, GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 43:560-567
23. Schneider J, Huh MM, Bradlow LH, Fishman J (1984) Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259:4840-4845
24. Fotsis T, Zhang Y, Pepper MS et al (1994) Endogenous estrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368:237-239
25. Cushman M, He HM, Katzenellenbogan JA, Lin CM, Hamel E (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38:2041-2049
26. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS (2010) Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57(2):171-192